Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Immunoreactive cells | |
Age | 24 | 61 | 74 | 27 | 25 | |
Sex | Male | Male | Female | Male | Male | |
VA | 20/40 | 20/400 | 2/200 | HM | HM | |
Duration | 11 years | 25 years | 30 years | 20 years | 3 years | |
Inflammation | Mild | None | Mild | Mild | None | |
LFA-1 | + | + | + | + | + | SI |
CD4 | + | + | + | + | + | SI |
CD8 | + | + | + | + | + | SI |
CD19 | − | − | − | − | − | |
CD68 | + | + | + | + | + | SI |
HLA-DR | + | + | + | + | + | SI, CCE, EV |
ICAM-1 | + | + | + | + | + | SI, CCE, EV |
IFN-γ | + | + | + | + | + | SI, CCE, EV |
IL-4 | − | − | − | − | − |
Age = age at surgery.
VA = visual acuity at the time of surgery.
Duration = duration from the initial attack to surgery.
HM = hand movement.
Inflammation = clinical inflammation at the time of surgery.
+ = immunoreactive.
− = not immunoreactive, apart from some immunoreactive polymorphonuclear cells in vascular lumen.
SI = subepithelial infiltrating cells.
CCE = conjunctivalised corneal epithelial cells.
EV = endothelial cells of blood vessel.